Empagliflozin in Acute Myocardial Infarction Reduces No-Reflow and Preserves Cardiac Function by Preventing Endothelial Damage

Panagiota-Efstathia Nikolaou, Lara SF. Konijnenberg,Ioannis V. Kostopoulos,Marios Miliotis,Nikolaos Mylonas,Anastasios Georgoulis,George Pavlidis, Carolien ΤΑ. Kuster, Vince PA. van Reijmersdal, Tom TJ. Luiken,Anna Agapaki, Rona Roverts, Nikolaos Orologas, Dimitris Grigoriadis, Gaëtan Pallot, Pierre Boucher,Nikolaos Kostomitsopoulos, Michael Paul Pieper, Stéphane Germain, Yannis Loukas

JACC Basic to Translational Science（2024）

引用 0|浏览0

暂无评分

摘要

Empagliflozin treatment before acute myocardial infarction mainly targets the endothelial cell transcriptome. Empagliflozin treatment pre- and post- myocardial infarction decreased no reflow and microvascular injury leading to reduced infiltration of inflammatory cells, reduced infarct size and improved cardiac function in mice. In diabetic patients receiving empagliflozin after myocardial infarction, perfused boundary region, flow-mediated dilation and global longitudinal strain were improved.

查看译文

关键词

empagliflozin,acute myocardial infarction,microvascular injury,no-reflow,cardiac magnetic resonance

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要